Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight

GlobeNewswire Inc. • Jan 14, 2026 1:00pm (New York) •By Delveinsight

Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight

The generalized myasthenia gravis (gMG) market is expected to grow significantly through 2034, driven by novel immunotherapies including FABHALTA (iptacopan) from Novartis, Descartes-08 from Cartesian Therapeutics, and Claseprubart from Dianthus Therapeutics. The 7MM had approximately 205,000 prevalent gMG cases in 2024, with increasing incidence projected. These emerging therapies represent a shift toward mechanism-driven treatments targeting refractory disease and improving long-term disease control.

← Back to news Read Original Article

Insights

NVS positive

FABHALTA (iptacopan) is positioned as a potentially first-in-class oral complement inhibitor for advanced gMG management with Phase III data expected by 2027, addressing significant unmet needs in refractory disease.

Keywords

#generalized myasthenia gravis #immunotherapy #complement inhibitors #FcRn antagonists #CAR T-cell therapy #autoimmune disease #drug pipeline #clinical trials

Tickers

NVS RNAC DNTH AZN ARGX JNJ

← Prev: ABX Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm

Next: Winnebago Industries Showcases Bold New RV Innovations Across Premium Brands at Florida RV SuperShow →